Oppenheimer & CO Inc Argenx Se Transaction History
Oppenheimer & CO Inc
- $6.52 Billion
- Q4 2024
A detailed history of Oppenheimer & CO Inc transactions in Argenx Se stock. As of the latest transaction made, Oppenheimer & CO Inc holds 830 shares of ARGX stock, worth $518,476. This represents 0.01% of its overall portfolio holdings.
Number of Shares
830
Previous 836
0.72%
Holding current value
$518,476
Previous $453,000
12.58%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding ARGX
# of Institutions
433Shares Held
29.2MCall Options Held
390KPut Options Held
272K-
Price T Rowe Associates Inc Baltimore, MD5.52MShares$3.45 Billion0.39% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.07MShares$1.92 Billion3.02% of portfolio
-
Janus Henderson Group PLC London, X02.31MShares$1.44 Billion0.76% of portfolio
-
Capital World Investors Los Angeles, CA1.79MShares$1.12 Billion0.17% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.24MShares$774 Million11.1% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $34.6B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...